ArticleScientific reports2025
Circulating CD24/Siglec-10 biomarkers predict post-resuscitation outcomes in a cardiac arrest cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Extracorporeal Cytokine Adsorption in Acute Cardiovascular Care: Pathophysiological Insights and Clinical Perspectives.Biomedicines · 2026Review
- CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation.Frontiers in immunology · 2026Review
- Systemic immune-inflammation index combined with blood urea nitrogen to albumin ratio predicts 28-day mortality in sepsis: a retrospective cohort study.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
CD24 can bind to its receptor, Siglec-10, and suppress immune responses induced by tissue damage. We aimed to study serum biomarkers in CD24/Siglec-10 axis and explore their associations with the survival and neurological prognosis of patients after return of spontaneous circulation (ROSC) following cardiac arrest. A prospective cohort study was performed. Eligible patients with ROSC were enrolled. Clinical information and serum levels of sCD24, sSiglec-10, sialic acid, tumor necrosis factor (TNF-α), interleukin-6 (IL-6), high mobility group protein 1 (HMGB1), neuron specific enolase (NSE), and neuraminidase activity were collected on days 1, 3 and 7 after ROSC. The 28-day survival and neurological outcome were documented. The study included 104 ROSC patients, with 30 and 74 in survivor and non-survivor groups, respectively. The levels of all biomarkers, except for sSiglec-10, sialic acid, and neuraminidases on day 1, were significantly higher in non-survivor than survivor group. Serum sCD24 level was positively correlated with sialic acid, HMGB1, TNF-α, IL-6, NSE, neuraminidases activity, and APACHE II score. Multivariate logistic regression analysis showed that serum sCD24 level was independently associated with 28-day poor neurological prognosis and mortality after ROSC. Multiple serum biomarkers within the CD24/Siglec-10 axis were significantly elevated following ROSC. Elevated serum sCD24 level emerged as a predictor of both 28-day poor neurological prognosis and all-cause mortality in patients after cardiac arrest. Further large-scale studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.